{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:40:10Z","timestamp":1750747210125,"version":"3.41.0"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Black and Hispanic\/Latine people are disproportionately affected by HIV\u20101 and may have a greater risk of comorbidities than non\u2010Black and non\u2010Hispanic\/Latine people with HIV. However, they have historically been underrepresented in HIV clinical studies. We aimed to assess the efficacy and safety of first\u2010line antiretroviral therapy with bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) over 5\u2009years in Black and Hispanic\/Latine people with HIV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present two post hoc pooled analyses of participants who received B\/F\/TAF up to week 240 in studies 1489 (NCT02607930) and 1490 (NCT02607956). Outcomes were compared between self\u2010identified Black and non\u2010Black participants and between Hispanic\/Latine and non\u2010Hispanic\/Latine participants, including baseline characteristics, proportion with HIV\u20101 RNA &lt;50\u2009copies\/mL, change in CD4 cell count, adherence, changes in metabolic parameters, and treatment\u2010emergent adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 211 Black, 421 non\u2010Black, 155 Hispanic\/Latine, and 477 non\u2010Hispanic\/Latine participants received B\/F\/TAF up to week 240. At baseline, median ages were 30\u201334\u2009years, and 84%\u201391% were male at birth. At week 240, high proportions of Black (97%), non\u2010Black (99%), Hispanic\/Latine (100%), and non\u2010Hispanic\/Latine (98%) participants had HIV\u20101 RNA &lt;50 copies\/mL. Black people with HIV were more likely than non\u2010Black people with HIV to have low (&lt;85%) adherence (11% vs. 5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0074). Changes in CD4 count, metabolic and renal parameters, and treatment\u2010emergent hypertension and diabetes were generally similar between Black and non\u2010Black and Hispanic\/Latine and non\u2010Hispanic\/Latine participants. A smaller proportion of Black than non\u2010Black people with HIV experienced study drug\u2010related treatment\u2010emergent adverse events (20% vs. 32%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0026).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results demonstrate the durability and long\u2010term safety of B\/F\/TAF in Black and Hispanic\/Latine people with HIV.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.70018","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:40:20Z","timestamp":1742730020000},"page":"858-869","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in Black and Hispanic\/Latine adults with <scp>HIV<\/scp>\u20101 initiating first\u2010line therapy: 5\u2010year follow\u2010up from two phase III studies"],"prefix":"10.1111","volume":"26","author":[{"given":"C.","family":"Martorell","sequence":"first","affiliation":[{"name":"The Research Institute  Springfield Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Immunology and Research Center  Fort Pierce Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hagins","sequence":"additional","affiliation":[{"name":"Chatham CARE Center  Savannah Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Osiyemi","sequence":"additional","affiliation":[{"name":"Triple O Research Institute  West Palm Beach Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Arribas","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Berhe","sequence":"additional","affiliation":[{"name":"North Texas Infectious Diseases Consultants  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Bichat Claude\u2010Bernard Hospital, AP\u2010HP  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Orkin","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Blizard Institute Queen Mary University  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Santiago","sequence":"additional","affiliation":[{"name":"HOPE Clinical Research  San Juan Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rosero","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Unger","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Liu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-3423","authenticated-orcid":false,"given":"J. T.","family":"Hindman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wurapa","sequence":"additional","affiliation":[{"name":"Infectious Disease Specialists of Atlanta  Decatur Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"UNAIDS.Global HIV & AIDS statistics fact sheet. Available at:https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed September 4 2024."},{"key":"e_1_2_13_3_1","unstructured":"Centers for Disease Control and Prevention.HIV surveillance report: diagnoses deaths and prevalence of HIV in the United States and 6 territories and freely associated states. Available at:https:\/\/stacks.cdc.gov\/view\/cdc\/156509. Accessed October 7 2024."},{"key":"e_1_2_13_4_1","unstructured":"HIV.gov.U.S. statistics. Available at:https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics. Accessed November 12 2024."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1501-14"},{"key":"e_1_2_13_6_1","unstructured":"NAM Publications.Black people and women are under\u2010represented in anti\u2010HIV drug studies. Available at:https:\/\/www.aidsmap.com\/news\/may\u20102020\/black\u2010people\u2010and\u2010women\u2010are\u2010under\u2010represented\u2010anti\u2010hiv\u2010drug\u2010studies. Accessed July 18 2024."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.676979"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.547"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70470-8"},{"key":"e_1_2_13_10_1","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents. Available at:https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult\u2010adolescent\u2010arv\/guidelines\u2010adult\u2010adolescent\u2010arv.pdf. Accessed October 17 2024."},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"e_1_2_13_12_1","unstructured":"European AIDS Clinical Society.Guidelines version 12.0. Available at:https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf. Accessed October 9 2024."},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)32340\u20101"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244"},{"key":"e_1_2_13_17_1","unstructured":"Gilead Sciences.Biktarvy (bictegravir emtricitabine and tenofovir alafenamide) [package insert]. Foster City CA: Gilead Sciences Inc.; September 2021. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210251s013lbl.pdf. Accessed June 27 2024."},{"volume-title":"Efficacy of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) Versus Dolutegravir (DTG)\u2010Based 3\u2010Drug Regimens in Adults with HIV Who Have Suboptimal Antiretroviral Adherence","year":"2023","author":"Andreatta K","key":"e_1_2_13_18_1"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn020"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29899"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz022"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31825db0bd"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263742"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181845589"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0256"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6940a1"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0091"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae191"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304146"},{"key":"e_1_2_13_31_1","unstructured":"European AIDS Clinical Society.European AIDS Clinical Society (EACS) interim guidance on the use of statin therapy for the primary prevention of cardiovascular disease in people with HIV. Available at:https:\/\/www.eacsociety.org\/media\/eacs_interim_guidance_on_statin_use_for_primary_prevention_cvd_in_people_with_hiv_2.pdf. Accessed November 12 2024."},{"key":"e_1_2_13_32_1","unstructured":"Centers for Disease Control and Prevention.National diabetes statistics report. Available at:https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/. Accessed Septebmer 4 2024."},{"key":"e_1_2_13_33_1","unstructured":"OstchegaY FryarCD NwankwoT NguyenDT.Hypertension prevalence among adults aged 18 and over: United States 2017\u20102018. NCHS Data Brief. No. 364. Available at:https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db364.htm. Accessed September 5 2024."},{"key":"e_1_2_13_34_1","unstructured":"National Kidney Foundation.Health disparities. Available at:https:\/\/www.kidney.org\/health-disparities. Accessed September 5 2024."},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:07:59Z","timestamp":1750745279000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/hiv.70018"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70018","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}